TH Global Capital Healthcare & Life Sciences advises Aqurance on sale to EY
TH Global Capital Healthcare & Life Sciences, a division of TH Global Capital, has completed a deal in Greece. The firm served as the exclusive financial advisor to Aqurance, a leading Veeva Premier Services Partner, on its sale to EY.
Established in 2011, Aqurance is a leading European Veeva partner with a mix of clinical, commercial and digital transformation services. With a dedicated team of 65 employees in Europe, and deep pharma expertise, Aqurance works with for life sciences companies globally.
For EY, the acquisition expands its expertise in Veeva applications in both commercial and research & development (R&D), as well as regulatory transformation and platform integration. The bolt-on also strengthen EY’s Veeva Centers of Excellence, which operates worldwide.
Dan Mathews, Global Life Sciences Leader at EY, said: “This is a pivotal moment for the industry as life sciences companies make critical decisions about platform migration, compliance and data integration. With the acquisition of Aqurance, EY can offer clients a more integrated pathway – strategy through execution – to unlock the full power of Veeva technology. Together, we will help companies move faster, stay compliant and use data and AI to help drive more informed decisions.”
The transaction
Dionissis Nikolopoulos, Founder and CEO of Aqurance, said that TH Global Capital played an instrumental role throughout the entire deal process.
“TH Global Capital Healthcare & Life Sciences was our key partner, bringing expertise and strategic guidance throughout the transaction. The team worked incredibly hard and were always by our side throughout and effortlessly navigated through the transaction, providing us with sound advice and helping us find solutions to any unforeseen challenges.”
“TH Global Capital’s understanding of the Veeva ecosystem, and their global buyer and investor network helped us identify the right strategic partner. We are truly thankful for the their guidance and unwavering support throughout this process.”
Vivek Subramanyam, Founder and CEO of TH Global Capital, commented, “We are incredibly excited to have completed this significant healthcare & life sciences transaction with EY. This transaction further highlights TH Global Capital’s global reach and deep capabilities in the life sciences and pharma ecosystem. We wish Aqurance every success in their strategic partnership with EY.”
Asif Shahinsha, Executive Director at TH Global Capital Healthcare and Life Sciences added: “We are delighted to have supported and advised Aqurance on this transaction. It was a widely sought asset, reflecting the demand for quality pharma and life sciences services companies in Europe. It has been a pleasure working with Aqurance and we’re excited to see what they’ll accomplish as part of the EY family.”
